IB Net Payout Yields Model

Pfizer: No Buy Signal After The Dip

Pfizer is down sharply over the last couple of months culminating with a decision to not split into two companies.
The company has a stock buyback plan, but chooses to use larger amounts of cash on making acquisitions such as paying $14 billion for Medivation.
Pfizer isn't a horrible stock to own, but the signals don't suggest outperformance for the next year.
At first glance, the multi-month drop in Pfizer (NYSE:PFE) appears to offer an opportunity. After all, the dividend is back to a respectable 3.5%.
Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Occidental: Still Producing Too Much Oil

ChargePoint: Low Quality Beat

Aurora Cannabis: Deal Or No Deal